
FDA Votes 9-1 to Advance Rexulti for Alzheimer’s
The FDA has approved the supplemental New Drug Application (sNDA) of REXULTI® (brexpiprazole) for the treatment of agitation associated with Alzheimer’s. It’s the first such treatment to be approved in the US. Learn more.